AI Engines For more Details: Perplexity Kagi Labs You
Antiseptic and Disinfectant: Dequalinium dichloride is often used as an antiseptic and disinfectant agent in topical preparations such as mouthwashes, throat lozenges, vaginal tablets, and skin creams. It is effective against a wide range of microorganisms, including bacteria (both gram-positive and gram-negative), fungi (such as Candida species), and some viruses.
Oral and Throat Infections: Dequalinium dichloride mouthwashes and throat lozenges are commonly used to treat oral infections, such as gingivitis, mouth ulcers, and sore throat. Its antiseptic properties help reduce the growth of bacteria in the mouth and throat, thereby alleviating symptoms and promoting healing.
Vaginal Infections: Dequalinium dichloride is also used in the form of vaginal tablets or suppositories to treat vaginal infections, including bacterial vaginosis and vaginal yeast infections (vulvovaginal candidiasis). It helps restore the natural balance of microorganisms in the vagina by suppressing the growth of harmful bacteria and fungi.
Skin Infections: In topical skin creams and ointments, dequalinium dichloride can be used to treat various skin infections, such as bacterial skin infections, fungal skin infections (such as athlete's foot and ringworm), and certain viral skin infections. It helps prevent the spread of infection and promotes healing of the affected skin.
Wound Healing: Dequalinium dichloride has been found to have wound-healing properties. When applied to wounds or cuts, it can help prevent infection and facilitate the healing process by reducing microbial contamination and promoting tissue repair.
Safety and Tolerance: Dequalinium dichloride is generally well-tolerated when used as directed. However, some individuals may experience mild irritation or allergic reactions at the site of application, especially if used in sensitive areas such as the mouth or genitals. It is important to follow the instructions provided by healthcare professionals or product labels when using dequalinium dichloride-containing products.
Pregnancy and Lactation: The safety of dequalinium dichloride use during pregnancy and breastfeeding has not been well studied. Therefore, pregnant or lactating individuals should consult healthcare professionals before using products containing dequalinium dichloride to assess potential risks and benefits.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bacteroides xylanisolvens | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.9 | 0.9 | 0 |
| ADHD | 5.4 | 2 | 1.7 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.7 | 3 | 0.23 |
| Allergies | 8.9 | 4.8 | 0.85 |
| Allergy to milk products | 2 | 1.6 | 0.25 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7.5 | 7.7 | -0.03 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.1 | 1.5 | 1.73 |
| Ankylosing spondylitis | 4.9 | 1.8 | 1.72 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 2.1 | 2.1 | |
| Asthma | 6.5 | 2.3 | 1.83 |
| Atherosclerosis | 2.7 | 2.8 | -0.04 |
| Atrial fibrillation | 4.1 | 2.8 | 0.46 |
| Autism | 10.8 | 10.5 | 0.03 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 3 | 3 | |
| Bipolar Disorder | 2.1 | 1.7 | 0.24 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.8 | 0.3 | 5 |
| Cancer (General) | 0.9 | 3.4 | -2.78 |
| Carcinoma | 4.9 | 2.6 | 0.88 |
| Celiac Disease | 3.6 | 3.5 | 0.03 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 6 | 7.1 | -0.18 |
| Chronic Kidney Disease | 5.2 | 2.6 | 1 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 3 | 2 | 0.5 |
| Chronic Urticaria (Hives) | 2 | 1.2 | 0.67 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 4.5 | 2.5 | 0.8 |
| Colorectal Cancer | 10.5 | 3.7 | 1.84 |
| Constipation | 2.7 | 2.5 | 0.08 |
| Coronary artery disease | 3 | 3 | 0 |
| COVID-19 | 11.5 | 14 | -0.22 |
| Crohn's Disease | 9.6 | 5.8 | 0.66 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.9 | -0.58 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 3.7 | 1.4 | 1.64 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 12.1 | 9.9 | 0.22 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 3.2 | -0.39 |
| Endometriosis | 3.5 | 2.6 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4 | 1.7 | 1.35 |
| erectile dysfunction | 2.6 | 0.3 | 7.67 |
| Fibromyalgia | 3.7 | 3.6 | 0.03 |
| Functional constipation / chronic idiopathic constipation | 6.9 | 4.9 | 0.41 |
| gallstone disease (gsd) | 4.4 | 1.1 | 3 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.4 | 2.5 | 0.36 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.4 | 1.4 | 0.71 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.5 | -0.67 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 3.9 | 1.5 | 1.6 |
| Heart Failure | 5.6 | 2.8 | 1 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 2 | 0.6 | 2.33 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 1.1 | |
| hyperglycemia | 2.4 | 1.1 | 1.18 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.7 | 6 | -0.28 |
| Hypothyroidism | 0.9 | 1 | -0.11 |
| Hypoxia | 3.6 | 0.9 | 3 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 11.4 | 10.4 | 0.1 |
| Insomnia | 3.4 | 2.4 | 0.42 |
| Intelligence | 2.6 | 0.6 | 3.33 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 9.4 | 5.3 | 0.77 |
| ischemic stroke | 3.2 | 1.7 | 0.88 |
| Liver Cirrhosis | 8.4 | 4 | 1.1 |
| Long COVID | 7.7 | 8.5 | -0.1 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.2 | 1 | 0.2 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 0.5 | 2.4 | -3.8 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.7 | 0.5 | 4.4 |
| Metabolic Syndrome | 8.1 | 8.2 | -0.01 |
| Mood Disorders | 11.4 | 8.4 | 0.36 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 8.2 | 7.8 | 0.05 |
| Multiple system atrophy (MSA) | 1.2 | 0.7 | 0.71 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.1 | -9.33 |
| Neuropathy (all types) | 0.7 | 3.1 | -3.43 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.5 | 4.8 | 0.35 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 11.5 | 8.9 | 0.29 |
| obsessive-compulsive disorder | 7 | 4.2 | 0.67 |
| Osteoarthritis | 3.3 | 1.2 | 1.75 |
| Osteoporosis | 3.1 | 1.6 | 0.94 |
| pancreatic cancer | 2.3 | 0.6 | 2.83 |
| Parkinson's Disease | 9.2 | 9.7 | -0.05 |
| Polycystic ovary syndrome | 7.9 | 2.9 | 1.72 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 3.9 | 3.4 | 0.15 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.8 | 4.7 | 0.87 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 7.5 | 3.1 | 1.42 |
| scoliosis | 0.9 | 0.9 | 0 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.3 | 0.6 | 2.83 |
| Stress / posttraumatic stress disorder | 3.2 | 2.7 | 0.19 |
| Systemic Lupus Erythematosus | 4.6 | 2.4 | 0.92 |
| Tic Disorder | 1.5 | 2.9 | -0.93 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 5.4 | 5 | 0.08 |
| Type 2 Diabetes | 9.7 | 8.5 | 0.14 |
| Ulcerative colitis | 7.6 | 8.6 | -0.13 |
| Unhealthy Ageing | 5.9 | 2.4 | 1.46 |
| Vitiligo | 2.5 | 1.5 | 0.67 |
